Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD): A Phase IV, Prospective, Randomized, Blinded, Parallel-group Trial

NCT07721922 is registered in ClinicalTrials.gov with University of Tennessee Graduate School of Medicine as lead sponsor.

NCT NCT07721922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07721922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD): A Phase IV, Prospective, Randomized, Blinded, Parallel-group Trial
Lead sponsor
University of Tennessee Graduate School of Medicine
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2028
Enrollment
280 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

copd exacerbation